Tumor Biology

, Volume 33, Issue 4, pp 979–984 | Cite as

CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls

  • Chibo Liu
  • Haibao Wang
  • Chunqin Pan
  • Jianmin Shen
  • Yong Liang
Research Article

Abstract

Many studies have suggested that cytochrome P450 2E1 (CYP2E1) gene might be involved in the development of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, the authors performed a meta-analysis to clarify the association between Pst I/Rsa polymorphism in the CYP2E1 gene and HCC risk. PubMed and China National Knowledge Infrastructure were searched for eligible publications. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects model. Fifteen studies (1,661 HCC cases and 2,317 controls) were identified for the data analysis. The overall result showed that there was no statistically significant association between CYP2E1 Pst I/Rsa polymorphism and HCC risk (c2/c2 vs. c1/c1, OR = 0.73, 95% CI 0.50–1.06; c1/c2 vs. c1/c1, OR = 1.00, 95% CI 0.76–1.33; c2/c2+ c1/c2 vs. c1/c1, OR = 0.99, 95% CI 0.77–1.26; c2/c2 vs. c1/c2+ c1/c1, OR = 0.73, 95% CI 0.50–1.06). Further stratified analyses indicated that the habitual alcohol drinkers with c2 alleles were more likely to develop HCC (OR = 1.73, 95% CI 1.19–2.51), compared with the non-habitual drinkers with c1 homozygote. The meta-analysis indicated that CYP2E1 Pst I/Rsa polymorphism was not associated with HCC risk, while the interaction between Pst I/Rsa polymorphism and alcohol consumption increased the risk of HCC.

Keywords

CYP2E1 Polymorphism Hepatocellular carcinoma Meta-analysis 

Notes

Acknowledgments

The work was funded by Zhejiang Medicine, Health, and Science (no.2010KYB127), China National Natural Science Fund (no. 81072209) and Zhejiang Gong Yi Xing Technology Application Project (no. 2011C33045). The author also thanks the Department of Laboratory Medicine, Taizhou Municipal Hospital for the support.

Conflicts of interest

None

References

  1. 1.
    Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol. 1991;4:168–79.PubMedCrossRefGoogle Scholar
  4. 4.
    Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, et al. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol. 1993;10:447–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Boccia S, De Lauretis A, Gianfagna F, van Duijn CM, Ricciardi G. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: a meta-analysis of the literature. Carcinogenesis. 2007;28:101–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhou GW, Hu J, Li Q. CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis. World J Gastroenterol. 2010;16:2949–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Niu Y, Hu Y, Wu M, Jiang F, Shen M, Tang C, et al. CYP2E1 Pst I/Rsa polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:607–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, Feng G, et al. The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case–control studies. BMC Cancer. 2010;10:575.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer. 2010;46:758–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Niu Y, Yuan H, Leng W, Pang Y, Gu N, Chen N. CYP2E1 Pst I/Rsa polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls. Med Oncol. 2011;28:182–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology. 1995;109:1266–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Ladero JM, Agúndez JA, Rodríguez-Lescure A, Diaz-Rubio M, Benítez J. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut. 1996;39:330–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H, Kim CY. Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma. Int J Cancer. 1997;71:737–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu CZ, Bian JC, Shen FM, Jiang F. Genetic polymorphism of cytochrome P450 2E1 and susceptibility to hepatocellular carcinoma. Cancer. 2000;19:862–4 (in Chinese).Google Scholar
  15. 15.
    Koide T, Ohno T, Huang XE, Iijima Y, Sugihara K, Mizokami M, et al. HBV/HCV infection, alcohol, tobacco and genetic polymorphisms for hepatocellular carcinoma in Nagoya, Japan. Asian Pac J Cancer Prev. 2000;1:237–43.PubMedGoogle Scholar
  16. 16.
    Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol. 2000;53:88–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Yu SZ, Huang XE, Koide T, Cheng G, Chen GC, Harada K, et al. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res. 2002;93:1287–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N, Mamada H, et al. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol. 2003;38:886–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003;129:355–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Silvestri L, Sonzogni L, De Silvestri A, Gritti C, Foti L, Zavaglia C, et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer. 2003;104:310–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Jiang AR, Wu JZ, Ding JH, Li SP, Cao HX, Su P, et al. Impact of CYP2E1 RsaI polymorphism on risk of hepatocellular carcinoma. Chin J Cancer Prev Treat. 2004;11:464–6 (in Chinese).Google Scholar
  22. 22.
    Wu XH, Yang XY, Duan W, Wang B, Yang SJ. The relationship between genetic polymorphism of cytochrome p450 and susceptibility to hepatocellular carcinoma. Acta Academiae Medicinae. 2007;16:47–8. 62 (in Chinese).Google Scholar
  23. 23.
    Ye XP, Peng T, Liu TW, Xiao KY, Su ZX, Shang LM, et al. The effect of interaction between alcohol drinking and polymorphisms of cytochrome P450 2E1 on the susceptibility of hepatocellular carcinoma in Guangxi region. J Guangxi Med University. 2008;25:493–5 (in Chinese).Google Scholar
  24. 24.
    Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M, Mizuta T, et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis. 2009;30:1729–34.PubMedCrossRefGoogle Scholar
  25. 25.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  27. 27.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRefGoogle Scholar
  28. 28.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu C, Liu L. Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol. 2011;32:1233–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu C. The association between AURKA T91A polymorphism and breast cancer risk. Breast Cancer Res Treat. 2011;129:281–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Thaler RH. The winner’s curse paradoxes and anomalies of economic life. Princeton: Princeton University Press; 1999.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Chibo Liu
    • 1
  • Haibao Wang
    • 1
  • Chunqin Pan
    • 1
  • Jianmin Shen
    • 1
  • Yong Liang
    • 1
  1. 1.Taizhou Municipal HospitalTaizhou UniversityTaizhouChina

Personalised recommendations